Central antihypertensive effects of orally active aminopeptidase a inhibitors in spontaneously hypertensive rats

Hypertension

Volumn 60, Issue 2, 2012, Pages 411-418

  Marc, Yannick ^a,c   Gao, Ji ^a   Balavoine, Fabrice ^a   Michaud, Annie ^a   Roques, Bernard P ^c,d   Llorens Cortes, Catherine ^a,b,c  

^a l'alimentation et l'Environnement   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c Quantum Genomics SA   (France)

^d Centre National de la Recherche Scientifique   (France)

Author keywords

aminopeptidase A inhibitors; blood pressure; brain renin Angiotensin system; hypertension; spontaneously hypertensive rats

Indexed keywords

AMINOPEPTIDASE A INHIBITOR; ANGIOTENSIN II; ANGIOTENSIN III; ANTIHYPERTENSIVE AGENT; ENALAPRIL; GLUTAMYL AMINOPEPTIDASE; MICROSOMAL AMINOPEPTIDASE; RB 150; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CONTROLLED STUDY; DIURESIS; DRUG BIOAVAILABILITY; DRUG POTENTIATION; ENZYME ACTIVITY; ENZYME STRUCTURE; ESSENTIAL HYPERTENSION; IN VIVO STUDY; KALIURESIS; MALE; MEAN ARTERIAL PRESSURE; NATRIURESIS; NONHUMAN; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; THERAPY EFFECT; VASCULAR RESISTANCE;

ADMINISTRATION, ORAL; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BRAIN; DISEASE MODELS, ANIMAL; DISULFIDES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRIL; ENZYME INHIBITORS; GLUTAMYL AMINOPEPTIDASE; HEART RATE; HYPERTENSION; MALE; RATS; RATS, INBRED SHR; RATS, INBRED WKY; RENIN-ANGIOTENSIN SYSTEM; SULFONIC ACIDS;

EID: 84864283868     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.112.190942     Document Type: Article

References (46)

1. Wolf-Maier K, Cooper RS, Kramer H, Banegas JR, Giampaoli S, Joffres MR, Poulter N, Primatesta P, Stegmayr B, Thamm M. Hypertension treatment and control in five European Countries, Canada, and the United States. Hypertension. 2004;43:10-17. (Pubitemid 38031904)
2. Radevski I, Skudicky D, Candy G, Sathekge S, Strugo V, Sareli P. Antihypertensive monotherapy with nisoldipine cc is superior to enalapril in Black patients with severe hypertension. Am J Hypertens. 1999;12: 94-204.
3. Saunders E, Weir MR, Kong BW, Hollifield J, Gray J, Vertes V, Sowers JR, Zemel MB, Curry C, Schoenberger J. A comparison of the efficacy and safety of a -blocker, a calcium channel blocker, and a converting enzyme inhibitor in hypertensive Blacks. Arch Intern Med. 1990;150: 1707-1713. (Pubitemid 20240985)
4. Matchar DB MD, Orlando LA, Patel MR, Patel UD, Patwardhan MB, Powers B, Samsa GP, Gray RN. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. Ann Intern Med. 2008;148:16-29. (Pubitemid 351664943)
5. Saine DR, Ahrens ER. Renal impairment associated with losartan. Ann Intern Med. 1996;124:775.
6. Johansen TL, Kjaer A. Reversible renal impairment induced by treatment with the angiotensin II receptor antagonist candesartan in a patient with bilateral renal artery stenosis. BMC Nephrol. 2001;2:1.
7. Oparil S, Chen Y, Berecek K, Calhoun D, Wyss J. The Role of the Central Nervous System in Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press; 1995.
8. Basso NRP, Mangiarua E, Taquini AC. Renin-like activity in the rat brain during the development of DOCA-salt hypertension. Hypertension. 1981; 3:14-17.
9. Ganten D, Hermann K, Bayer C, Unger T, Lang RE. Angiotensin synthesis in the brain and increased turnover in hypertensive rats. Science. 1983;221:869-871. (Pubitemid 13034290)
10. Guyenet P. The sympathetic control of blood pressure. Nat Rev Neurosci. 2006;7:335-346.
11. Morimoto S, Cassell MD, Beltz TG, Johnson AK, Davisson RL, Sigmund CD. Elevated blood pressure in transgenic mice with brain-specific expression of human angiotensinogen driven by the glial fibrillary acidic protein promoter. Circ Res. 2001;89:365-372. (Pubitemid 34132676)
12. Davisson RL YG, Beltz TG, Cassell MD, Johnson AK, Sigmund CD. The brain renin-Angiotensin system contributes to the hypertension in mice containing both the human renin and human angiotensinogen transgenes. Circ Res. 1998;16:1047-1058. (Pubitemid 28520934)
13. Yongue BG, Angulo JA, McEwen BS, Myers MM. Brain and liver angiotensinogen messenger RNA in genetic hypertensive and normotensive rats. Hypertension. 1991;17:485-491.
14. Phillips MI, Kimura B. Brain angiotensin in the developing spontaneously hypertensive rat. J Hypertens. 1988;6:607-612.
15. Schelling P, Meyer D, Loos HE, Speck G, Phillips MI, Johnson AK, Ganten D. A micromethod for the measurement of renin in brain nuclei: its application in spontaneously hypertensive rats. Neuropharmacology. 1982;21:455-463. (Pubitemid 12112504)
16. Gutkind JS, Kurihara M, Castren E, Saavedra JM. Increased concentration of angiotensin II binding sites in selected brain areas of spontaneously hypertensive rats. J Hypertens. 1988;6:79-84. (Pubitemid 18063304)
17. Masuyama Y, Tsuda K, Kuchii M, Nishio I. Peripheral neural mechanism of hypertension in rat models: peripheral sympathetic neurotransmission in hypertension. J Hypertens. 1986;4(suppl)S189-S192. (Pubitemid 17209470)
18. Nishimura M, Ohtsuka K, Sakamoto M, Nanbu A, Takahashi H, Yoshimura M. Roles of brain angiotensin II and C-type natriuretic peptide in deoxycorticosterone acetate-salt hypertension in rats. J Hypertens. 1998;16:1175-1185. (Pubitemid 28334020)
19. Czyzewski LB, Pettinger WA. Failure of feedback suppression of renin release in the spontaneously hypertensive rat. Am J Physiol. 1973;225: 234-239.
20. Fournie-Zaluski MC, Fassot C, Valentin B, Djordjijevic D, Reaux-Le Goazigo A, Corvol P, Roques BP, Llorens-Cortes C. Brain reninangiotensin system blockade by systemically active aminopeptidase a inhibitors: A potential treatment of salt-dependent hypertension. Proc Natl Acad Sci USA. 2004;101:7775-7780. (Pubitemid 38678554)
21. Grobe JL, Xu D, Sigmund CD. An intracellular renin-Angiotensin system in neurons: fact, hypothesis, or fantasy. Physiology. 2008;23: 187-193.
22. Zini S, Fournie-Zaluski MC, Chauvel E, Roques BP, Corvol P, Llorens-Cortes C. Identification of metabolic pathways of brain angiotensin II and III using specific aminopeptidase inhibitors: predominant role of angiotensin III in the control of vasopressin release. Proc Natl Acad Sci USA. 1996;93:11968-11973. (Pubitemid 26347232)
23. Fournie-Zaluski MC, Coric P, Turcaud S, Lucas E, Noble F, Maldonado R, Roques BP. Potent and systemically active aminopeptidase N inhibitors designed from active site investigation. J Med Chem. 1992;35: 1259-1266.
24. Chauvel EN, Llorens-Cortes C, Coric P, Wilk S, Roques BP, Fournie-Zaluski MC. Differential inhibition of aminopeptidase A and aminopeptidase N by new -Amino thiols. J Med Chem. 1994;37:2950-2957. (Pubitemid 24297812)
25. Reaux A, Fournie-Zaluski MC, David C, Zini S, Roques BP, Corvol P, Llorens-Cortes C. Aminopeptidase A inhibitors as potential central antihypertensive agents. Proc Natl Acad Sci USA. 1999;96:13415-13420.
26. Reaux A, de Mota N, Zini S, Cadel S, Fournie-Zaluski M, Roques BP, Corvol P, Llorens-Cortes C. PC18, a specific aminopeptidase N inhibitor, induces vasopressin release by increasing the half-life of brain angiotensin III. Neuroendocrinology. 1999;69:370-376. (Pubitemid 29240410)
27. Wright JW, Tamura-Myers E, Wilson WL, Roques BP, Llorens-Cortes C, Speth RC, Harding JW. Conversion of brain angiotensin II to angiotensin III is critical for pressor response in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R725-R733. (Pubitemid 36342805)
28. Reaux A, Fournie-Zaluski MC, Llorens-Cortes C. Angiotensin III: A central regulator of vasopressin release and blood pressure. Trends Endocrinol Metab. 2001;12:157-162. (Pubitemid 33713556)
29. Bodineau L, Frugiere A, Marc Y, Inguimbert N, Fassot C, Balavoine F, Roques B, Llorens-Cortes C. Orally active aminopeptidase A inhibitors reduce blood pressure: A new strategy for treating hypertension. Hypertension. 2008;51:1318-1325. (Pubitemid 351555944)
30. Vazeux G, Wang J, Corvol P, Llorens-Cortes C. Identification of glutamate residues essential for catalytic activity and zinc coordination in aminopeptidase A. J Biol Chem. 1996;271:9069-9074. (Pubitemid 26123339)
31. Rozenfeld R, Iturrioz X, Maigret B, Llorens-Cortes C. Contribution of molecular modeling and site-directed mutagenesis to the identification of two structural residues, Arg-220 and Asp-227, in aminopeptidase A. J Biol Chem. 2002;277:29242-29252.
32. Nakamura A, Johns EJ. Renal nerves, renin, and angiotensinogen gene expression in spontaneously hypertensive rats. Hypertension. 1995; 581-586.
33. Okuno TNS, Lindheimer MD, Oparil S. Attenuation of the development of spontaneous hypertension in rats by chronic central administration of captopril. Hypertension. 1983;5:653-662. (Pubitemid 14230763)
34. Zini S, Masdehors P, Lenkei Z, Fournie-Zaluski MC, Roques BP, Corvol P, Llorens-Cortes C. Aminopeptidase A: distribution in rat brain nuclei and increased activity in spontaneously hypertensive rats. Neuroscience. 1997;78:1187-1193. (Pubitemid 27223720)
35. Phillips MI, Mann JFE, Haebara H, Hoffman WE, Dietz R, Schelling P, Ganten D. Lowering of hypertension by central saralasin in the absence of plasma renin. Nature. 1977;270:445-447. (Pubitemid 8229411)
36. Hutchinson JS, Doyle AE. Hypotensive effects of captopril, saralasin and bromocriptine in spontaneously hypertensive rats. Clin Sci (Lond). 1980; 59(suppl 6)79s-82s. (Pubitemid 11222889)
37. Lee JM, Zhai G, Liu Q, Gonzales ER, Yin K, Yan P, Hsu CY, Vo KD, Lin W. Vascular permeability precedes spontaneous intracerebral hemorrhage in stroke-prone spontaneously hypertensive rats. Stroke. 2007; 38:3289-3291. (Pubitemid 350175751)
38. Von Lutterotti N, Camargo MJ, Campbell WGJ, Mueller FB, Timmermans PB, Sealey JE, Laragh JH. Angiotensin II receptor antagonist delays renal damage and stroke in salt-loaded Dahl salt-sensitive rats. J Hypertens. 1992;10:949-957.
39. Lin KS, Chan JY, Chan SH. Involvement of AT2 receptors at NRVL in tonic baroreflex suppression by endogenous angiotensins. Am J Physiol. 1997;272:2204-2210.
40. Phillips MI. Functions of angiotensin in the central nervous system. Annu Rev Physiol. 1987;49:413-435. (Pubitemid 17053904)
41. Marc Y, Llorens-Cortes C. The role of the brain renin-Angiotensin systemin hypertension: Implications for new treatment. Prog Neurobiol. 2011;95:89-103.
42. Mathias C. Management of hypertension by reduction in sympathetic activity. Hypertension. 1991;4:69-74.
43. Huang BS, Ahmad M, Roques BP, Llorens-Cortes C, Leenen FHH. Brain Ang III inhibition attenuates sympathetic hyperactivity and LV dysfunction in rat post myocardial infarction (MI). FASEB J. 2011;25: 843.17.
44. De Mota N, Itturioz X, Claperon C, Bodineau L, Fassot C, Roques BP, Palkovits M, Llorens-Cortes C. Human brain Aminopeptidase A: biochemical properties and distribution in brain nuclei. J Neurochem. 2008; 106:416-428. (Pubitemid 351840224)
45. Allen AM. Inhibition of the hypothalamic paraventricular nucleus in spontaneously hypertensive rats dramatically reduces sympathetic vasomotor tone. Hypertension. 2002;39:275-280. (Pubitemid 34165228)
46. Wright JW, Harding JW. Brain renin-Angiotensin: A new look at an old system. Prog Neurobiol. 2011;95:49-67.